InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.45
(
0.57%
)
Bitcoin
68,546.95
(
0.05%
)
Post# of 251942
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 106208

Friday, 08/19/2016 7:03:04 PM

Friday, August 19, 2016 7:03:04 PM

Post# of 251942
FDA approves PFE’s Troxyca (oxycodone/naltrexone)—the only oxycodone product that carries an FDA label with a description of its abuse-resistant features:

http://finance.yahoo.com/news/fda-approves-troxyca-er-oxycodone-222100823.html

PFE acquired Troxyca in the 2010 buyout of King Pharmaceuticals (#msg-55425514).

The King deal also gave PFE Embeda, a morphine/naltrexone combination that was FDA-approved in 2009.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up